Evidence map›Paper›PMID 26183281›Full record

ArticleScientific reports2015

A standardized and reproducible protocol for serum-free monolayer culturing of primary paediatric brain tumours to be utilized for therapeutic assays.

Emma Sandén, Sofia Eberstål, Edward Visse, Peter Siesjö, Anna Darabi

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. BioMed research international · 2017
    Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Emma SandénGlioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Sofia EberstålGlioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Edward VisseGlioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Peter Siesjö1] Glioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences Lund, Lund University, Lund, Sweden [2] Division of Neurosurgery, Department of Clinical Sciences Lund, Skåne University Hospital, Lund, Sweden.
Anna DarabiGlioma Immunotherapy Group, Division of Neurosurgery, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Lund University · SESkåne University Hospital · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In vitro cultured brain tumour cells are indispensable tools for drug screening and therapeutic development. Serum-free culture conditions tentatively preserve the features of the original tumour, but commonly comprise neurosphere propagation, which is a technically challenging procedure. Here, we define a simple, non-expensive and reproducible serum-free cell culture protocol for establishment and propagation of primary paediatric brain tumour cultures as adherent monolayers. The success rates for establishment of primary cultures (including medulloblastomas, atypical rhabdoid tumour, ependymomas and astrocytomas) were 65% (11/17) and 78% (14/18) for sphere cultures and monolayers respectively. Monolayer culturing was particularly feasible for less aggressive tumour subsets, where neurosphere cultures could not be generated. We show by immunofluorescent labelling that monolayers display phenotypic similarities with corresponding sphere cultures and primary tumours, and secrete clinically relevant inflammatory factors, including PGE2, VEGF, IL-6, IL-8 and IL-15. Moreover, secretion of PGE2 was considerably reduced by treatment with the COX-2 inhibitor Valdecoxib, demonstrating the functional utility of our newly established monolayer for preclinical therapeutic assays. Our findings suggest that this culture method could increase the availability and comparability of clinically representative in vitro models of paediatric brain tumours, and encourages further molecular evaluation of serum-free monolayer cultures.

Indexed as

Culture Media, Serum-FreeDrug Screening Assays, AntitumorPrimary Cell CultureAdolescentAntigens, CDAntineoplastic AgentsBiomarkersBrain NeoplasmsCell AdhesionCell ProliferationChildChild, PreschoolCyclooxygenase 2CytokinesDinoprostoneFemaleAntigens, CDAntineoplastic AgentsBiomarkersCulture Media, Serum-FreeCyclooxygenase 2CytokinesDinoprostone

Identifiers

PMID26183281
PMCPMC4505308
OpenAlexW1757544626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.